Navigation Links
nContact Announces Initiation of Clinical Trials for the Treatment of Atrial Fibrillation in Open-Chest Procedures
Date:11/16/2009

MORRISVILLE, N.C., Nov. 16 /PRNewswire/ -- nContact Surgical, Inc. ("nContact"), a leader in the investigation of devices for non-invasive treatment for heart conditions, today announced the initiation of a clinical trial designed to evaluate the safety and efficacy of its Numeris® - AF Tethered Coagulation System with VisiTrax® device in an open-chest concomitant procedure for the treatment of longstanding persistent atrial fibrillation (AF). This multi-center, non-randomized, prospective clinical trial will enroll up to 107 participants at 15 study sites across the United States.

"We developed our coagulation system based on the integration of suction, perfusion, and energy to create non-conductive, bi-atrial lesions. What is unique about this study is that we are creating a comprehensive lesion pattern on a beating heart to interrupt atrial fibrillation circuits located across both atria," said John P. Funkhouser, President and CEO of nContact. "Our hope is that this study will lead to participants being free from AF and completely off class I and class III antiarrhythmic drugs (AADs)* following their treatment."

The clinical trial procedure involves creating a bi-atrial lesion pattern on a beating heart to block electrical signals that cause AF. The lesions are created using nContact's tethered device on the upper chambers of the heart, the left and right atria, where the AF occurs. Once the lesions have been created, a cardiothoracic surgeon will be able to confirm intra-operatively through pacing whether the lesions are non-conductive and the pulmonary veins are isolated.

"The nContact technology enables me to create a comprehensive biatrial lesion pattern on a beating heart. We look forward to investigating the ability to treat atrial fibrillation in patients undergoing open heart surgery with the hope of establishing the lesion pattern with superior results," commented Dr. Edward Garrett, Jr., Principal Investigator from Baptist Memorial Hospital Heart Institute, Memphis.

For more information about the Numeris-AF Tethered Coagulation with VisiTrax trial, please visit www.clinicaltrials.gov (study number NCT00950092).

*The decision to stop the use of AADs will be decided by each participant's physician evaluation of the participant's medical status.

About nContact Surgical, Inc .

nContact is a medical device company founded in 2005 with the company mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF).

To date, The Numeris® Coagulation System with VisiTrax® is indicated for the coagulation of cardiac tissue (resulting in lesion creation) in the United States. nContact has initiated clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the specific indication for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter.

    nContact, Inc.
    1001 Aviation Parkway, Ste 400
    Morrisville, NC  27560
    T (919) 466-9810
    F (919) 466-9811

    Media Contacts
    Angela Moser
    nContact Surgical, Inc.
    amoser@ncontactsurgical.com

    Scott Lerman
    The Ruth Group
    T (646) 536-7013
    slerman@theruthgroup.com

SOURCE nContact Surgical, Inc.


'/>"/>
SOURCE nContact Surgical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. China Medicine Announces Strong Third Quarter 2009 Results
2. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
3. Chindex International Announces Participation in Brean Murray, Carret & Co. 2009 China Growth Conference
4. LifeCare Holdings, Inc. Announces Third Quarter Results
5. Telik Announces Third Quarter 2009 Financial Results
6. Quantros Announces Partnership With Hospital Accreditation Agency DNV
7. Misonix Announces New Distribution Agreement For The United Arab Emirates (UAE)
8. Dynatronics Announces Positive Financial Results for Quarter
9. Niusule Announces Key Additions to Management Team
10. Warner Chilcott Announces Secondary Equity Offering
11. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... ZappRx, Inc ., a digital health company focused on modernizing ... closed $25 million in Series B funding led by Qiming ... Seattle that is part of a broader ... round included participation from SR One , who led ... (formerly Google Ventures). As part of the financing, Mark ...
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 26, 2017 , ... Want to learn more about CRISPR-Cas ... that demonstrates how this advanced plant breeding technology is a more efficient way ... resources. It highlights the business’ principles, research and collaboration efforts in this area. ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, a medical ... that it has received 510(k) clearance from the U.S. Food & Drug Administration ... Pro. , Both devices are stationary cycling systems that use MYOLYN’s patent-pending ...
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab ... to be the preferred physical therapy provider for Derby City CrossFit, effective immediately. ... City CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will ...
(Date:4/25/2017)... IN (PRWEB) , ... April 25, 2017 , ... ... D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration could ... Financial will provide insight into what changes are most likely to make it ...
(Date:4/25/2017)... ... , ... Lake Park Dental is now accepting new patients with crooked teeth ... With the help of this highly-effective, yet convenient system, patients can straighten their teeth ... less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth Dy, ...
Breaking Medicine News(10 mins):